ICON plc (ICLR) exhibits 45.0% gross margins and 3.1% return on invested capital within Health Care (Biotechnology: Commercial Physical & Biological Resarch), balanced against a 31.7x enterprise multiple and 4.8% implied options volatility.
Sustained 45.0% gross profitability converts into 5.4% operating margin and 3.1% ROIC, outpacing sector cost of capital.
ROIC: 3.1% // GM: 45.0%YoY revenue trajectory of +0.8% paired with 5.22% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +0.8% // FCF YLD: 5.22%Altman Z-Score of 2.20 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 2.20 // F-SCORE: 7/9Trading at 71.9x trailing P/E (66.9x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 71.9x // EV/EBITDA: 31.7xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $211.36 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Commercial Physical & Biological Resarch require continuous execution to defend 2.8% net margins.
NET MARGIN: 2.8% // D/E: 0.31x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for ICLR & activate live FRED threshold breach alerts.